Published in ACS Chem Biol on December 23, 2014
Exquisitely specific bisubstrate inhibitors of c-Src kinase. ACS Chem Biol (2015) 0.78
Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration. ACS Med Chem Lett (2015) 0.76
Evolution and intelligent design in drug development. Front Mol Biosci (2015) 0.75
The protein kinase complement of the human genome. Science (2002) 35.36
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Oncogenic kinase signalling. Nature (2001) 16.30
Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J (1995) 14.45
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol (2006) 12.09
Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol (2005) 11.74
Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell (1995) 9.27
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Protein kinases--the major drug targets of the twenty-first century? Nat Rev Drug Discov (2002) 7.38
New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem (2010) 6.54
Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (1995) 6.16
Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev (2002) 6.05
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
Activation and signaling of the p38 MAP kinase pathway. Cell Res (2005) 5.48
JNK signaling in apoptosis. Oncogene (2008) 4.72
Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J (1997) 4.59
p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov (2003) 4.58
Features of selective kinase inhibitors. Chem Biol (2005) 4.07
Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nat Struct Biol (2002) 3.77
Protein tyrosine kinase structure and function. Annu Rev Biochem (2000) 3.62
Strategies to overcome resistance to targeted protein kinase inhibitors. Nat Rev Drug Discov (2004) 3.25
Protein phosphorylation in signaling--50 years and counting. Trends Biochem Sci (2005) 3.19
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem (1989) 3.02
Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol (2006) 2.96
Kinomics: methods for deciphering the kinome. Nat Methods (2005) 2.94
Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (1988) 2.35
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site. Proc Natl Acad Sci U S A (2008) 2.26
The structural basis for control of eukaryotic protein kinases. Annu Rev Biochem (2012) 2.21
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure (1999) 2.09
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol (2007) 1.88
Protein phosphorylation and signal transduction. Pharmacol Ther (1999) 1.79
Tyrphostins and other tyrosine kinase inhibitors. Annu Rev Biochem (2006) 1.70
Piceatannol (3,4,3',5'-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun (1989) 1.46
Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res (2012) 1.33
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. J Am Chem Soc (2007) 1.28
Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc (2008) 1.26
Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem (1991) 1.22
Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J Am Chem Soc (2005) 1.21
Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol Ther (1998) 1.17
Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther (1999) 1.17
Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res (2009) 1.10
Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry (2000) 1.10
Development of paramagnetic probes for molecular recognition studies in protein kinases. J Med Chem (2008) 1.09
Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther (2008) 1.09
High-throughput screening for kinase inhibitors. Chembiochem (2005) 1.08
Tyrosine kinases as targets for cancer therapy. Eur J Cancer (2002) 1.05
Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today (2009) 1.05
Identification of selective, nonpeptidic nitrile inhibitors of cathepsin s using the substrate activity screening method. J Med Chem (2006) 1.05
Protein tyrosine kinases: structure, substrate specificity, and drug discovery. Biopolymers (1998) 1.04
Protein tyrosine kinase-substrate interactions. Curr Opin Struct Biol (2006) 1.02
Identification and evaluation of small molecule pan-caspase inhibitors in Huntington's disease models. Chem Biol (2010) 1.02
Chemical influences on the specificity of tyrosine phosphorylation. J Biol Chem (1990) 1.02
Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv (2009) 1.00
Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim Biophys Acta (2005) 0.99
Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod (1984) 0.99
Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. ACS Chem Biol (2011) 0.99
Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight. Biochemistry (2012) 0.98
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer. Breast Cancer Res Treat (2011) 0.98
Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Commun (1987) 0.95
Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol (1994) 0.95
Principles of competitive binding assays (saturation analysis). 1. Equilibrium techniques. Clin Chem (1973) 0.95
Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors. ACS Chem Biol (2010) 0.94
Specific inhibitors of tyrosine-specific protein kinases: properties of 4-hydroxycinnamamide derivatives in vitro. Cancer Res (1989) 0.94
Protein kinase inhibition: different approaches to selective inhibitor design. Curr Drug Targets (2006) 0.93
Sequence and structural analysis of kinase ATP pocket residues. Farmaco (2004) 0.91
An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model. J Proteomics (2012) 0.90
Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Nat Chem Biol (2012) 0.90
A scaffold makes the switch. Sci Signal (2008) 0.89
Kinetic studies of tyrosine kinase inhibition by erbstatin. J Antibiot (Tokyo) (1987) 0.89
Assay principle for modulators of protein-protein interactions and its application to non-ATP-competitive ligands targeting protein kinase A. Anal Chem (2006) 0.87
Peptide inhibitors targeting protein kinases. Curr Pharm Des (2009) 0.87
Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors. J Med Chem (2012) 0.87
Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts. Mol Cancer Ther (2012) 0.87
Bivalent inhibitors of protein kinases. Crit Rev Biochem Mol Biol (2014) 0.86
A rationale for the design of an inhibitor of tyrosyl kinase. J Biol Chem (1990) 0.86
Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors. Anal Biochem (2010) 0.86
Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. Chembiochem (2005) 0.86
Development of Src tyrosine kinase substrate binding site inhibitors. Curr Opin Investig Drugs (2008) 0.85
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells. Leukemia (2010) 0.85
Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases. Curr Pharm Des (2012) 0.85
Evolution of domain combinations in protein kinases and its implications for functional diversity. Prog Biophys Mol Biol (2009) 0.85
Inhibition of protein kinase C by the tyrosine kinase inhibitor erbstatin. Biochem Pharmacol (1990) 0.84
Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase. J Med Chem (2013) 0.83
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res (2013) 0.83
The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study. Eur J Med Chem (2012) 0.83
Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors. Angew Chem Int Ed Engl (2014) 0.82
High-affinity bisubstrate probe for fluorescence anisotropy binding/displacement assays with protein kinases PKA and ROCK. Anal Biochem (2008) 0.82
The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. Bioorg Med Chem Lett (2000) 0.81
A novel Pim-1 kinase inhibitor targeting residues that bind the substrate peptide. J Mol Biol (2012) 0.81
Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance. J Med Chem (2010) 0.80
Effect of posttranslational modifications on enzyme function and assembly. J Proteomics (2013) 0.80
Detection of allosteric kinase inhibitors by displacement of active site probes. J Biomol Screen (2012) 0.80
Screening of protein kinases by ATP-STD NMR spectroscopy. J Am Chem Soc (2005) 0.79
Kinetics and mechanism of angiotensin phosphorylation by the transforming gene product of Rous sarcoma virus. J Biol Chem (1984) 0.78
Surface-plasmon-resonance-based biosensor with immobilized bisubstrate analog inhibitor for the determination of affinities of ATP- and protein-competitive ligands of cAMP-dependent protein kinase. Anal Biochem (2006) 0.78
The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 2: hydroxyindole derivatives. Bioorg Med Chem Lett (2000) 0.78
Exploiting substrate recognition for selective inhibition of protein kinases. Curr Pharm Des (2012) 0.78
Chemical synthesis of proteins. Annu Rev Biophys Biomol Struct (2005) 1.71
Protein assembly by orthogonal chemical ligation methods. J Am Chem Soc (2003) 1.14
Development of a highly selective c-Src kinase inhibitor. ACS Chem Biol (2012) 1.14
Water-soluble phosphinothiols for traceless staudinger ligation and integration with expressed protein ligation. J Am Chem Soc (2007) 1.14
Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid). J Biol Chem (2003) 1.05
Protein prosthesis: 1,5-disubstituted[1,2,3]triazoles as cis-peptide bond surrogates. J Am Chem Soc (2007) 1.04
Tandem cytochrome P450 monooxygenase genes and splice variants in the white rot fungus Phanerochaete chrysosporium: cloning, sequence analysis, and regulation of differential expression. Fungal Genet Biol (2003) 0.92
Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine. ACS Chem Biol (2012) 0.90
A general method for detecting protease activity via gelation and its application to artificial clotting. Chem Commun (Camb) (2012) 0.89
Enzyme-triggered gelation: targeting proteases with internal cleavage sites. Chem Commun (Camb) (2014) 0.84
Activation state-selective kinase inhibitor assay based on ion mobility-mass spectrometry. Anal Chem (2013) 0.83
Substrate activity screening with kinases: discovery of small-molecule substrate-competitive c-Src inhibitors. Angew Chem Int Ed Engl (2014) 0.82
Electronic and steric effects on the rate of the traceless Staudinger ligation. Org Biomol Chem (2008) 0.81
Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. ACS Chem Biol (2016) 0.81
Human glycinamide ribonucleotide transformylase: active site mutants as mechanistic probes. Biochemistry (2007) 0.80
Synthetic surfaces for ribonuclease adsorption. Langmuir (2005) 0.78
Development of a chimeric c-Src kinase and HDAC inhibitor. ACS Med Chem Lett (2013) 0.76